Added to YB: 2025-01-23
Pitch date: 2024-12-06
ACE.ST [bullish]
Ascelia Pharma AB (publ)
-1.16%
current return
Author Info
No bio for this author
Company Info
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions.
Market Cap
SEK 303.2M
Pitch Price
SEK 3.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.15
P/E
-1.93
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Ascelia Pharma AB - $ACE.ST
ACE.ST: Orviglance liver MRI agent for renal patients completed Phase III, FDA submission mid-2025. $800M global market, no competitors, 80% margins. Undervalued at $26M cap ($7.5M cash). Strong M&A potential in radiopharmaceuticals. Key catalysts: commercialization partner, FDA approval.
Read full article (32 min)